MedTrace Logo

Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes

NCT03973827 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-03-07

No results posted yet for this study

Summary

An open label, parallel single centre trial of Wharton's Jelly derived allogenic mesenchymal stromal cells repeated treatment to preserve endogenous insulin production in adult patients diagnosed with type 1 diabetes

Conditions

  • Type1diabetes

Interventions

DRUG

ProTrans

Single infusion of 25, 100 or 200 million cells per patient.

OTHER

Control

No intervention. Control subjects.

Sponsors & Collaborators

  • NextCell Pharma Ab

    lead INDUSTRY

Principal Investigators

  • Per-Ola Carlsson, PhD · Uppsala University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
41 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-17
Primary Completion
2020-12-10
Completion
2024-11-20

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973827 on ClinicalTrials.gov